New Amsterdam Sciences Announces Pre-IND Phase 2 Submission with FDA Coronavirus Treatment Acceleration Program for NAS150

Scottsdale, AZ,  May 14th, 2021 – New Amsterdam Sciences, a privately held company, announces the filing of the Company’s newly provided materials and data with the FDA’s coronavirus treatment acceleration program as a pre-Investigation New Drug Phase 2 submission. The FDA submission is for the advancement of the Company’s therapeutic agent Read more…

PR Distribution Services
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.